Tag: androgen deprivation therapy (ADT)
1. Enzalutamide along with androgen-deprivation therapy was shown to significantly increase median overall survival among men with non-metastatic, castration-resistant prostate cancer.
2. Adverse events for enzalutamide and androgen-deprivation therapy were shown to be consistent with the established safety profile of enzalutamide.
Evidence Rating Level: 1 (Excellent)
Study Rundown: Enzalutamide is an approved therapy for...
1. Enzalutamide along with androgen-deprivation therapy was shown to significantly increase median overall survival among men with non-metastatic, castration-resistant prostate cancer.
2. Adverse events for enzalutamide and androgen-deprivation therapy were shown to be consistent with the established safety profile of enzalutamide.
Evidence Rating Level: 1 (Excellent)
Study Rundown: Enzalutamide is an approved...
Androgen deprivation therapy (ADT) is used in the treatment of prostate cancer, either alone or in combination with other treatment modalities. ADT, however, is not without long-term effects, with patients commonly experiencing sexual dysfunction, in addition to conferring an increased risk of cardiovascular events. ADT exposure may also increase...
2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: long-term follow-up of a multicentre, randomised trial
The ideal surgical excision margin for patients with thick (>2 mm) localized cutaneous melanomas is unclear, where the risk of recurrence must be weighed against excess morbidity resulting from...